azelastine HCl

ApprovedSmall molecule

MMeda Pharmaceuticals

azelastine HCl is one of 37 small molecule programs targeting Allergic Rhinitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Vasomotor RhinitisActive, not recruiting

Allergic RhinitisPhase 3

Active, not recruiting

Vasomotor RhinitisApproved

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Asmanex Hfa

PPerrigo Company

Phase 3

5 2

Sudafed

KKenvue Brands

Phase 3

3 3

Flovent

PParatek Pharmaceuticals Inc

Phase 3

2 4

Rayos

RRoxane Laboratories

Phase 3

1 5

Kenalog

BBassett Healthcare

Phase 3

1 6

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 7

Active Comparator

Moderna

Phase 3

1 8

azelastine HCl

MMeda Pharmaceuticals

Approved

1 9

Allegra-D

Pfizer

Phase 3

3 10

Asmanex

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness3 trials

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed·MMeda Pharmaceuticals·Phase 3·NCT00651118·832 enrolled

A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed·MMeda Pharmaceuticals·Phase 3·NCT00740792·776 enrolled

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed·MMeda Pharmaceuticals·Phase 3·NCT00660517·607 enrolled

Allergic Rhinitis1 trial

Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis

Completed·HHanlim Pharm. Co., Ltd.·Phase 3·NCT01470053·347 enrolled

Vasomotor Rhinitis1 trial

Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

Completed·AAlcon Research·Phase 4·NCT00979615·129 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for azelastine HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — azelastine HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for azelastine HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Meda Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMeda Pharmaceuticals

azelastine HCl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness3 trials

Allergic Rhinitis1 trial

Vasomotor Rhinitis1 trial

References

Drug Info

Quick Facts

Related News